This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Multiple sclerosis is quietly shifting how drugmakers define success. Instead of judging a therapy mainly by whether it reduces relapses, developers are chasing the slower, harder-to-treat processes that drive long-term disability, and Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is one of the companies […]
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
- Researchers recognize that a large share of long-term disability accumulates independent of relapses altogether, a phenomenon researchers call progression independent of relapse activity.
- That shift has forced researchers to look at what is actually driving PIRA. A major suspect is chronic active lesions, sometimes called smoldering or mixed active-inactive lesions.
- Rather than broadly suppressing the immune system, Quantum BioPharma’s Lucid-MS is designed to inhibit myelin degradation, preserve myelin and support functional recovery.
Multiple sclerosis is quietly shifting how drugmakers define success. Instead of judging a therapy mainly by whether it reduces relapses, developers are chasing the slower, harder-to-treat processes that drive long-term disability, and Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is one of the companies building a therapy around that shift, through its myelin-focused candidate Lucid-MS.
Questions around this news
What does progression independent of relapse activity mean in multiple sclerosis?
Progression independent of relapse activity, or PIRA, describes worsening disability in multiple sclerosis that occurs apart from identifiable relapses. The term reflects a distinction between short-term flare-ups and gradual changes that can accumulate over time. The release says researchers are paying greater attention to this process when studying the sources of long-term disability.
What are chronic active lesions in multiple sclerosis?
Chronic active lesions are areas of ongoing disease activity in the brain or spinal cord. They may also be described as smoldering or mixed active-inactive lesions. The release identifies them as a major suspected contributor to PIRA, while noting that researchers are investigating what drives disability apart from relapses.
Why are researchers looking beyond relapse rates to assess multiple sclerosis treatments?
Relapse rates capture flare-ups, but they may not reflect all processes behind disability that develops over time. The release says researchers recognize that substantial long-term disability can accumulate independently of relapses. This has encouraged drug developers to investigate slower processes, including PIRA, as they consider how to assess treatment effects.
For decades, MS treatment success was measured largely by relapse rates. Fewer flare-ups meant a drug was working. But researchers now recognize that a substantial proportion of long-term disability accumulates independent of…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
At a glance
- Company
- Quantum BioPharma Ltd.
- Ticker
- NASDAQ: QNTM, CSE: QNTM
- Announcement
- Product
Products and programs
SEC filings
Earlier from Quantum BioPharma Ltd.
- Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS into Phase 2
- Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances MS Imaging Study with Encouraging Preliminary Results
- Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions
- Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Expands Clinical Development of Neuroprotective Therapy
- Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
